viewOpen Orphan PLC

Open Orphan signs preferred partnership with Ipsen Group

The partnership will last three years, and has "already delivered substantial revenues"

Open Orphan Plc -
Open Orphan group completed the reverse takeover of clinical trials company Venn Life Sciences in June

Open Orphan Plc (LON:ORPH) has announced plans to make its Venn Life Sciences business profitable by way of a three-year preferred partnership agreement with French pharma company Ipsen Group.

In a statement on Monday, the AIM-listed rare disease drug developer said that Venn Life Sciences, which the Open Orphan group reversed into this year, will be the preferred partner for Ipsen's data management and biostatistics divisions.

READ: Open Orphan inks software deal

The company said that the partnership has “already delivered substantial revenues”, and positions the business as an integrated drug development partner for biopharma companies in Europe such as Ipsen.

In a statement, Open Orphan’s chief executive Cathal Frie said: “This partnership is the first of many steps to make Venn profitable and deliver a re-rating of the business to be in line with the wider sector.”

He pointed out that Open Orphan plans to restructure the business to reduce operational leverage, increase revenue, improve operating margins and launch additional complementary services.

Open Orphan announced the £5.7mln reverse takeover of listed clinical trials group Venn Life Sciences in June.

Quick facts: Open Orphan PLC

Price: 18.125 GBX

Market: AIM
Market Cap: £120.69 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Open Orphan PLC named herein, including the promotion by the Company of Open Orphan PLC in any Content on the Site, the Company receives from...


Open Orphan PLC: Proactive One2One Virtual Conference

Open Orphan PLC's (LON:ORPH) Cathal Friel presents at the Proactive One2One Virtual Conference. The company's a rapidly growing specialist CRO pharmaceutical services company which is a world leader in the testing of vaccines and antivirals through the use of human challenge clinical trials. It...

4 weeks, 2 days ago

2 min read